Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXC007 in idiopathic pulmonary fibrosis
ISRCTN60385283Phase 2Completed
- Sponsor
- Redx Pharma
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of zelasudil in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Redx Pharma. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Change in safety laboratory parameters and 2 more. Started Jun 2022; status: completed.
02
Drugs
zelasudil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ISRCTN60385283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN60385283.